Pre-made Pinatuzumab benchmark antibody ( Whole mAb ADC, anti-CD22 therapeutic antibody, Anti-SIGLEC2/SIGLEC-2 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Pinatuzumab biosimilar, Whole mAb ADC, Anti-CD22 Antibody: Anti-SIGLEC2/SIGLEC-2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Pinatuzumab vedotin (DCDT2980S, FCU2703) is an anti-CD22 antibody-drug conjugate (ADC) developed by Genentech/ Hoffmann-La Roche for the treatment of diffuse large B-cell lymphoma (DLBCL). … Pinatuzumab vedotin has proved its efficacy in inducing a complete tumor regression in xenograft lymphoma models.
| Products Name (INN Index) | Pre-Made Pinatuzumab biosimilar, Whole mAb ADC, Anti-CD22 Antibody: Anti-SIGLEC2/SIGLEC-2 therapeutic antibody |
|---|---|
| INN Name | Pinatuzumab |
| Target | CD22 |
| Format | Whole mAb ADC |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | 6and:HL |
| 95-98% SI Structure | None |
| Year Proposed | 2012 |
| Year Recommended | 2013 |
| Companies | Genentech |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Chronic lymphocytic leukaemia,Diffuse large B cell lymphoma,Non-Hodgkin's lymphoma |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CD22 |
| Package |
